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Abstract 
Aim: To describe the clinical features, treatment and outcomes in Australian adults with focal 
segmental glomerulosclerosis and identify predictors of disease progression and all-cause 
mortality. 
Methods: The study included all patients with biopsy confirmed focal segmental 
glomerulosclerosis between January 1997 and June 2014 at participating hospitals. Clinical 
factors, histopathological findings, biochemical markers and treatments were analysed and 
potential predictors of doubling serum creatinine, end stage kidney disease or death identified. 
Results: 98 patients were included with a median follow-up of 4.3 years. 34 (35%) patients 
were Aboriginal or Torres Strait Islander. Focal segmental glomerulosclerosis not-otherwise-
specified was the most common variant. 17 (59%) patients initially treated with 
immunosuppression experienced an improvement in renal function. At the end of follow-up 
43 (44%) patients had progressed to the composite outcome. Baseline tubulointerstitial 
scarring and lower haemoglobin predicted shorter time to doubling serum creatinine. Dual 
diagnosis, higher serum creatinine, lower estimated glomerular filtration rate and doubling 
creatinine were associated with shorter time to end stage kidney disease with remission the 
only protective factor. Age was the only variable associated with all-cause mortality.  
Conclusion: Focal segmental glomerulosclerosis holds serious implications for patients. 
Concomitant diabetic nephropathy, higher serum creatinine and lower estimated glomerular 
filtration rate at renal biopsy were associated with poorer renal prognosis. Indigenous people 
had a female predominance and are over-represented in relation to their population size, 
however were not associated with poorer prognosis. Remission was the only modifiable 
variable and thus should be at the forefront of patient management goals and future studies.  
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Introduction 
Focal Segmental Glomerulosclerosis (FSGS) is a pathologic term that is characterised by the 
presence of focal and segmental glomerular sclerotic lesions. It has a complex aetiology and 
can be classified into primary and secondary FSGS. Primary FSGS is diagnosed in over 80% 
of cases, and is a diagnosis of exclusion.
(1)
 The disease trends towards progressive decline of 
renal function to end stage kidney disease (ESKD) within 5-10 years in over 50% of cases
.(2, 3) 
In 2011, FSGS was the second leading cause of all new glomerulonephritis cases resulting in 
ESKD in Australia.
(4) 
These rates are on the rise internationally with some countries reporting 
a 3-13 fold increase in incidence over the past two decades.
(5-8) 
The increasing incidence of ESKD attributable to FSGS and its associated burden on patients 
and their families that has prompted renewed interest in this disease. 
The purpose of the study was to describe the clinical features, treatment and outcomes of 
primary and secondary FSGS in Far North Queensland Australian adults and to identify any 
predictors of disease progression and all-cause mortality. 
Methods 
The human research ethics committee for the participating hospitals (HREC/13/QHC/031) 
and affiliated university (H5707) approved the study. A retrospective review was conducted 
of patients’ medical records and pathology reports to record clinical, histopathological, 
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biochemical and medication details. Informed patient consent was waived due to the 
retrospective nature of the study.   
Settings and patients 
All incident patients with biopsy proven FSGS at Cairns and Townsville Hospitals between 
January 1997 and June 2014 were included. Patients younger than 18 years old were 
excluded. We analysed the FSGS cases as a single group due to difficulty distinguishing 
between primary and secondary cases.  
Clinical presentation, disease profile and study endpoints 
The following baseline clinical variables were recorded at the time of renal biopsy: patient 
age, gender, ethnicity, BMI, comorbidities (diabetes, cerebrovascular disease, 
hypercholesterolemia, hypertension and infection), smoking status, haematuria (macro- and 
microscopic findings) and oedema.  
Histopathological findings including variant (Columbia Classification), additional diagnosis 
and degree of tubulointerstitial scarring were obtained from biopsy results reported at the 
Princess Alexandra Hospital pathology department. 
(9)
 Degree of tubulointerstitial scarring 
was based on the scoring system which has been better defined in transplant biopsies; mild 
(≤25), moderate (26-50%) and severe (>50%). (10) 
A retrospective review of the electronic pathology system was performed to record the 
following baseline biochemical parameters: haemoglobin, platelets, total white cell count and 
differential, serum creatinine, serum albumin, estimated glomerular filtration rate, albumin-
creatinine ratio, protein-creatinine ratio and 24 hour urinary protein. Estimated glomerular 
filtration rate (eGFR) was calculated using the CKD-EPI equation. Nephrotic range 
proteinuria was classified as >3g protein/day. 
(11)
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Medication information was retrieved from patient records. The use of the following 
medications was recorded: diuretics, angiotensin converting enzyme inhibitors or angiotensin 
II receptor blockers, immunosuppression (prednisolone, cyclosporine A, cyclophosphamide) 
as was subsequent treatment response. Complete remission was defined as a daily urine 
protein excretion of <0.3 g/d, partial remission was defined as ≥50% reduction of proteinuria 
from baseline. Relapse was defined by a single proteinuria value ≥3 g/d after any 
remission.
(12)
 
Patients were followed until June 2014, death or lost to follow-up. The primary endpoint of 
the study was a composite outcome of doubling of serum creatinine, progression to ESKD or 
all-cause mortality. Each of these three separate outcomes was also investigated as secondary 
endpoints. Baseline patient and biochemical characteristics were recorded at the time of renal 
biopsy.  ESKD was defined as eGFR <15mL/min/1.73m
2 
  or commencement of dialysis.  
Kidney transplantation was intentionally excluded due to an incomplete data set, with a 
significant proportion of the cohort transplant status unknown. None of the transplants 
received were pre-emptive, hence transplant status was not relevant when it came to reaching 
the endpoint of ESKD. 
Statistical analysis 
All data were recorded and analysed using SPSS (IBM, Version 22).  Descriptive statistics 
were calculated for the study cohort and reported as mean +/- standard deviation or median 
and range for continuous data, depending on distribution, and frequency (%) for categorical 
variables. All decimal values were rounded to two significant figures. 
Comparison of Aboriginal and Torres Strait Islander and non-Aboriginal and Torres Strait 
Islander patients at baseline was made using Students two sample t-test for continuous 
variables and chi square for observations measured with a nominal scale. 
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The association of clinical, biochemical and treatment related variables with progression to 
the composite and secondary study endpoints were analysed using unadjusted (univariate) 
Cox regression analysis. P values <0.05 were considered significant. Significant variables in 
univariate analysis were entered into a correlation matrix to evaluate zero order correlations. 
If two independent variables correlated with a Pearson correlation coefficient of greater than 
0.6 (with p<0.05), one of them was excluded. Remaining independent variables were entered 
into adjusted (multivariate forward stepwise) Cox regression model to determine the final 
predictors of progression to the composite outcome.   
Results 
During the study period, 98 patients had biopsy proven FSGS. 10 were lost to follow-up. The 
remaining patients were followed-up for a median of 4.32 years (range 0-16.5 years).  
Baseline characteristics 
There was an equal gender distribution with a median age of 45 years.  Approximately one 
third of patients were Aboriginal or Torres Strait Islanders who had statistically significant 
greater rates of comorbidities including diabetes, hypertension, cardiovascular disease and 
dyslipidaemia (Table 1). Nephrotic range proteinuria was observed in 50 (51%) patients.  The 
median serum creatinine and eGFR at the time of biopsy was 131μmol/L and 53ml/min 
respectively (Table 2). 
Histopathological findings 
Mild tubulointerstitial scarring was present in 46 (47%) patients and another 18 (20%) had 
severe scarring. FSGS not-otherwise-specified (NOS) was the most common variant 
identified in 85 (87%) patients. Dual diagnosis was identified in 22 (22%) of patients; the 
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most common underlying renal disease was diabetic nephropathy which affected 8 (8.2%) 
patients within the cohort.  
Treatment modalities 
Immunosuppression was given to 30 (30%) patients initially. Of these, 24 (80%) received 
prednisolone at an average dose of 1mg/kg/day for a duration of six weeks. Over half of these 
patients improved their renal function by the end of the follow-up period, with only 29 (43%) 
patients receiving conservative management alone improving their renal function. Complete 
remission was achieved in one- third of the entire cohort. Conservative management with 
diuretics, angiotensin-converting-enzyme inhibitors and angiotensin II receptor blockers were 
used in 26 (88%) patients receiving immunosuppression with angiotensin-converting-enzyme 
inhibitors the most commonly used agent. Approximately 70% of the patients that received 
immunosuppression suffered a relapse.  
Treatment outcomes 
At the end of follow-up, 43 (44%) patients had progressed to the composite outcome. One-
third doubled their serum creatinine within a median time of 2.9 years (range 0.2-11.3 years). 
Progression to ESKD occurred in 37 (38%) patients in a median period of 1.6 years (range 0-
12.4 years). Death from any cause occurred in 18 (19%) patients during the follow-up period.  
Predictors of renal outcomes 
Indicators of more severe disease at baseline as well as failure to achieve or sustain a 
remission were the only prognostic factors identifiable. A worse prognosis was associated 
with histopathological findings of diabetic nephropathy (Table 3), tubulointerstitial scarring 
(Table 4) or ―dual diagnosis‖ (Table 5). A worse prognosis was also linked to baseline 
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increased serum creatinine (Table 3), reduced eGFR (Table 3+5) and anaemia (Table 4). As 
expected higher age at baseline was linked to earlier death (Table 6). 
Discussion 
Studies involving primary FSGS in adults have shown it to be a disease encompassing 
different demographic characteristics, clinical manifestations, treatment regimens and 
outcomes. We examined these aspects in an attempt to identify clinically important variables 
which may guide management and further improve our understanding of this disease in the 
Australian population, particularly with its unique Aboriginal and Torres Strait Islander 
population.  
The cohort included in our study is unique. The catchment of hospitals involved encompasses 
Aboriginal and Torres-Strait Islanders from remote and very remote locations. The 
Indigenous population was over-represented accounting for one-third of the cohort despite 
comprising only 7.8% and 5.5% of the Cairns and Townsville populations respectively. 
Surprisingly, ethnicity was not identified as a significant predictor towards poorer outcomes. 
Regardless, the Indigenous population did show marked increased rates of comorbidities 
(diabetes, cardiovascular disease, hypertension, hypercholesterolaemia), diabetic nephropathy 
and severe tubulointerstitial scarring which in itself hold implications for morbidity and 
mortality.
(13-15) 
 
Within our study 21% of the ATSI participants had a dual histological diagnosis, of which 
only 15% was diabetic nephropathy. This is an important observation as renal disease within 
Indigenous Australians is frequently attributed to Type 2 Diabetes. Whilst nearly half of the 
Indigenous patients within the study had diabetes, fewer than half of these had diabetic 
nephropathy on biopsy. Hoy et al. reports a similar finding with only one quarter of the 
remote/very remote Aboriginal people having definitive diabetic change on biopsy.
(13)
 This 
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highlights the important role of renal biopsies even within diabetic populations, where 
diabetic nephropathy may not be the primary cause of renal disease. 
The female excess within our Indigenous cohort is consistent with the analyses of remote and 
very remote Indigenous biopsies by Hoy et al. This pattern of disease differs from that 
witnessed within urban Indigenous Australians and is likely related to a combination of 
socioeconomic and environmental conditions. Female predominance is difficult to explain 
but may be related to lower female birth weight – associated with nephropenia and 
compensatory glomerulomegaly. Female gender is itself associated with lower nephron 
number.
(13, 16)
 High rates of diabetes until mid-life and greater central fat distribution may 
also contribute.
(13)
  
The Columbia classification is a widely used system to classify FSGS into five histological 
variants based entirely on light microscopic findings; tip, perihilar, cellular, collapsing and 
not-otherwise specified.
 (17)
 Several studies have analysed differences in clinical 
characteristics and outcomes between these variants.
(18)
  It has been reported that the 
collapsing variant confers poorer prognosis whilst the tip variant has better survival and 
remission rates. 
(19, 20)
 Cellular and collapsing variants have also been shown to be more 
common in African-Americans. 
(21)
 In this study the collapsing and cellular variants were 
only identified in two biopsies each. Due to the small number of these histological variants in 
our cohort we were unable to comment on the prognostic significance of any of the variants.  
The proportion of patients given immunosuppression was lower in this population compared 
to previous studies which averaged over 60%.
(21-23)
 This may be due to the fact that previous 
studies consisted of entirely primary FSGS cohorts in which immunosuppression is 
considered the mainstay of treatment.
(11)
 This study made no differentiation between primary 
and secondary FSGS due to the difficulty in clinically distinguishing between the two in a 
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retrospective setting. No single test exists to differentiate primary and secondary FSGS with 
the exclusion of secondary causes being particularly challenging in this population given the 
frequency of comorbidities and dual diagnoses. Furthermore defining primary and secondary 
FSGS based purely on treatment is not sufficient, and was consequently decided against. 
It has been documented that 50% of patients with nephrotic-range proteinuria develop ESKD 
within 6-8 years.
(23)
 In this study, 38% developed ESKD over a median period of 1.6 years. 
This may have been foreshortened due to the exclusion of the period between the incident 
presentation with FSGS to the time it was confirmed by renal biopsy. Additionally late 
presentation to the participating health centre may have been influenced by such factors as 
travel time, cost and health care accessibility from more remote areas.   
Lower haemoglobin and high serum creatinine were associated with significant progression 
of renal disease.  Interestingly, lower haemoglobin was found to be a biochemical marker of 
time for progression to doubling of serum creatinine. Whilst anaemia has long been 
associated with chronic kidney disease, few authors, including have Chou et al. have 
demonstrated any relationship between lower haemoglobin and doubling of serum 
creatinine.
(24)
 The pathophysiology behind this finding requires further investigation. Stirling 
et al. reported that patients with serum creatinine >100μmol/l at disease onset had a 
significantly poorer prognosis than those whose creatinine was <100μmol/l.(25) In our study, 
the prognostic value of serum creatinine at biopsy with respect to ESKD was strengthened 
only when tubulointerstitial scarring was included. .  
In multivariate Cox regression analysis, age was only a predictor of death and did not predict 
the composite outcome, doubling of serum creatinine, or progression to ESKD. Whilst age is 
a component of the CKD-EPI formula for estimating glomerular filtration rate, any 
relationship between age, eGFR and the measured outcomes is adjusted for through 
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multivariate Cox regression analysis. For example, whilst age was a significant predictor of 
the composite outcome in univariate analysis, this became non-significant compared to 
baseline serum creatinine in the adjusted Cox regression analysis (Table 3). 
Several studies have demonstrated that achievement of remission confers favourable 
prognosis.
(26-28)
 This study strengthens this observation with remission found to be the only 
protective variable. The large, multi-centre study by Troyanov et al. found that 
immunosuppression through high-dose prednisolone was associated with a higher rate of 
partial and complete remission.
(29)
 Whilst there was a trend towards steroid responsiveness 
and reduced risk of ESKD in our study (p=0.052) it was likely that the small number of 
primary FSGS cases limited the study’s statistical power to demonstrate this association.  
There are several limitations of our study that challenge the interpretation of our results. Our 
study was retrospective in design, with all the inherent drawbacks of such an approach. The 
other limitation related to potential sample bias.  Patients were only included in the study if 
they underwent a renal biopsy. This may have led to under representation as not all patients 
with FSGS underwent biopsies for reasons such as geographic location, failure to attend or a 
clinical decision that biopsy was unnecessary.  
To the best of our knowledge, this is the first study of its kind in patients with FSGS in North 
Queensland. In addition it is also valuable due to the significant portion of Aboriginal or 
Torres Strait Islander patients. This study may improve the understanding of the disease 
profile of FSGS and identification of risk factors for poor renal outcomes in this unique 
patient population. It underscores the need to ensure appropriate exclusion of secondary 
causes to enable suitable treatment with immunosuppression to optimize remission rates. 
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Further work to elucidate the underlying pathophysiology of these prognostic variables may 
enhance our understanding of this disease in addition to guiding future trial priorities and 
treatment regimes.  
Conclusion 
Concomitant diabetic nephropathy, higher serum creatinine and lower eGFR at renal biopsy 
were associated with poor renal prognosis. Aboriginal or Torres Strait Islander people are 
over-represented in relation to their population size, and more females were affected but there 
was no difference in potential for progression to outcomes. Achievement of remission 
remains the single most important modifiable variable for renal survival and thus should be at 
the forefront of patient management goals.  
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Table 1. Baseline characteristics at time of FSGS diagnosis and follow-up period 
 
Clinical Variable 
 
All 
(n = 98) 
 
Non- Aboriginal and 
Torres Strait 
Islander  
(n = 64) 
 
Aboriginal and 
Torres Strait 
Islander  
(n = 34) 
 
 
P 
value
 
 
Age (median) (years) 
 
45 (range 20-88) 
 
46 (range 20—88) 
 
44 (range 20-70) 
 
0.28 
Male (%) 50 61 
 
29 
 
0.003 
 
Body mass index
1
 (%) 
Underweight 
Average 
Overweight 
Obese 
 
28 
28 
35 
8.2 
 
33 
27 
35 
5.5 
 
20 
30 
37 
13 
0.16 
Comorbidities (%) 
Diabetes 
Cardiovascular disease 
Hypercholesterolemia 
Hypertension 
Infection 
 
29 
27 
66 
78 
4.4 
 
20 
19 
57 
72 
1.7 
 
47 
43 
83 
90 
9.7 
 
0.01 
0.02 
0.01 
0.04 
0.08 
Smoking status (%) 
Never smoked 
Ever smoked 
 
41 
59 
 
44 
56 
 
37 
63 
0.81 
 
 
Clinical findings (%) 
Haematuria
2 
Oedema
3 
 
45 
49 
 
46 
49 
 
42 
49 
 
0.76 
0.96 
Follow-up (median) 
(years) 
4.3 (range 0-17) 3.5 (range 0-17) 4.8 (range 0-15) 0.47 
 
1
Body mass index: underweight (BMI <18.5), average (BMI 18.5-24.9), overweight (BMI 25.0-29), 
obese (BMI >30) 
2
Haematuria: included both micro and macroscopic haematuria 
3
Oedema: clinically noted, degree unspecified 
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Table 2. Biochemical results at time of FSGS diagnosis  
 
Biochemical Marker 
 
Median 
 
Range 
 
Haemoglobin (g/L) 129 81-172 
White cell count (10
9
/L) 8.9 4-27 
Neutrophils  (10
9
/L) 5.9 2-6.4 
Lymphocytes  (10
9
/L) 1.8 0-1 
Platelets  (10
9
/L) 258 132-1852 
Serum protein  (g/dL) 68 9-88 
Serum albumin (g/dL) 34 15-46 
Serum creatinine (μmol/L) 131 0-1450 
PCR (mg/mmol) 291 7-1700 
ACR (mg/mmol) 240 2-1100 
24hr urinary protein (mg/24hr) 3100 70-18000 
eGFR (mL/min) 53 2-134 
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Table 3.  Predictors towards the composite event of worsening of any outcome parameter 
 Unadjusted Cox regression Adjusted Cox regression‡ 
Independent variable Numbers p-value Hazards ratio (95% CI) p-
value 
Hazards ratio 
(95% CI) 
Clinical factors      
Age in decades 
 
98 0.001 1.5 (1.2-1.9) -----
 
-----
 
----- 
----- 
Male gender 98 0.90 1.0 (0.57-1.9)   
Ethnicity 98 0.51 0.81 (0.42-1.5)   
Diabetes 93 0.03 2.1 (1.1-3.9) ----- 
----- 
----- 
----- 
Hypertension 91 0.64 1.3 (0.45-3.7)   
Hypercholesterolemia 90 0.54 1.3 (0.61-2.6)   
Cardiovascular 
disease 
88 0.004 2.6 (1.4-5.1) ----- 
----- 
----- 
----- 
Ever smoked 87 0.56 1.2 (0.62-2.4)   
Infection 90 0.58 1.5 (0.36-6.3)   
Body mass index 98 0.22 0.79 (0.55-1.2)   
Haematuria 92 0.32 1.4 (0.73-2.6)   
Oedema 88 0.07 1.9 (0.94-3.7)   
Lesion factors      
Dual diagnosis 98 0.003 2.8 (1.4-5.5) ----- 
----- 
----- 
----- 
Diabetic nephropathy 98 0.004 3.4 (1.5-7.8) ----- 
0.021 
----- 
11 (1.4-87) 
IgA nephropathy 98 0.43 0.44 (0.06-3.3)   
Acute tubular 
necrosis 
98 0.006 5.6 (1.7-19) ----- 
----- 
----- 
----- 
NOS variant 98 0.09 3.5 (0.83-15)   
Tip variant 98 0.29 0.34 (0.05-2.5)   
Perihilar variant 98 0.84 0.05 ( 5.3x10
-15 – 
4.5x10
11
) 
  
Collapsing variant 98 0.63 0.05 (2.0x10
-7
 -  
11.5x10
3
) 
  
Cellular variant 98 0.29 0.33 (0.04-2.6)   
Tubulointerstitial 
Scarring 
98 <0.001 1.9 (1.4-2.7) ----- 
----- 
----- 
----- 
Biochemical factors      
Haemoglobin (g/L)
† 
91 0.001 0.78 (0.67-0.91) ----- 
----- 
----- 
----- 
White cell count 
(10
9
/L)
 
91 0.079  1.1 (0.99-1.2)   
Platelets (10
9
/L)
†
 90 0.15 0.97 (0.92-1.0)   
Neutrophils(10
9
/L) 89 0.44 1.0 (1.0-1.0)   
Lymphocytes (10
9
/L) 89 0.602 0.99 (0.97-1.0)   
Serum creatinine 
(μmol/L)† 
92 <0.001 1.0 (1.0-1.0) 0.001 
----- 
1.3 (1.1-1.5) 
----- 
Serum albumin 
(g/dL)
†
 
77 0.23 0.71 (0.41-1.2)   
Serum protein (g/dL)
†
 70 0.14 1.0 (0.99-1.1)   
Albumin creatinine 
ratio (mg/mmol)
†
 
57 0.045 1.0 (1.0-1.0) ----- 
----- 
----- 
----- 
Protein creatinine 81 0.21  1.0 (1.0-1.0)   
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ratio (mg/mmol)
†
 
24hr urinary protein 
(mg/24hr)
†
 
81 0.23 1.0 (1.0-1.0)   
eGFR (mL/min)
†
 91 <0.001 0.74 (0.65-0.86) ----- 
0.001 
----- 
0.54 (0.37-0.78) 
Treatment      
Angiotensin-
converting-enzyme 
inhibitor 
85 0.84 0.93 (0.46-1.9)   
Angiotensin II 
receptor blocker 
81 0.12 0.37 (0.11-1.3)   
Angiotensin-
converting-enzyme 
inhibitor/ angiotensin 
II receptor blocker 
84 0.06 0.49 (0.23-1.0)   
Diuretics 83 0.73 1.1 (0.57-2.2)   
Immunosuppression 83 0.024 2.4 (1.1-5.0)   
Remission 91 0.003 0.48 (0.29-0.78) 0.045 
0.037 
0.29 (0.09-0.97) 
0.29 (0.09-0.93) 
Complete remission 91 0.006 0.13 (0.03-0.56) ----- 
----- 
----- 
----- 
Partial remission 91 0.63 1.2 (0.55-2.6)   
Relapse 50 0.20 0.57 (0.24-1.3)   
Steroid response 22 0.12 0.34 (0.09-1.3)   
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Table 4. Predictors towards the event of doubling serum creatinine 
 Unadjusted Cox regression 
 
Adjusted Cox regression‡ 
Independent variable Numbers p-value Hazards ratio (95% CI) p-
value 
Hazards ratio 
(95% CI) 
Clinical factors      
Age in decades  80 0.01 1.4 (1.1-1.8) -----
 
-----
 
----- 
----- 
Male gender 80 0.38 1.4 (0.68-2.8)   
Ethnicity 80 0.78 0.90 (0.43-1.9)   
Diabetes 79 0.01 2.6 (1.3-5.3) ----- 
----- 
----- 
----- 
Hypertension 78 0.03 8.6 (1.2-63) ----- 
----- 
----- 
----- 
Hypercholesterolemia 79 0.67 1.2 (0.53-2.7)   
Cardiovascular 
disease 
77 0.05 2.1 (1.0-4.3)   
Ever smoked 76 0.96 0.98 (0.48-2.0)   
Infection 78 0.09 3.5 (0.81-15)   
Body mass index 74 0.75 0.94 (0.64-1.4)   
Haematuria 76 0.82 1.1 (0.53-2.3)   
Oedema 74 0.12 1.9 (0.86-4.0)   
Lesion factors      
Dual diagnosis 80 0.04 2.2 (1.0-4.8) ----- 
----- 
----- 
----- 
Diabetic nephropathy 80 0.02 3.4 (1.3-9.2) ----- 
----- 
----- 
----- 
IgA nephropathy 80 0.59 0.58 (0.08-4.3)   
Acute tubular 
necrosis 
80 0.68 1.5 (0.21-11)   
NOS variant 80 0.36 2.0 (0.47-8.3)   
Tip variant 80 0.41 0.43 (0.06-3.2)   
Perihilar variant 80 0.85 0.05 (3.6x10
-15
 – 
6.6x10
10
) 
  
Collapsing variant 80 0.53 0.05 (3x10
6
-7x10
2
)   
Cellular variant 80 0.55 1.8 (0.25-13)   
Tubulointerstitial 
Scarring 
80 <0.001
 2.9 (1.8-4.5) 0.005 
----- 
2.5 (1.3-4.9) 
----- 
Biochemical factors      
Haemoglobin (g/L)
†
  78 0.004 0.76 (0.64-0.92) 0.004 
0.006 
0.62 (0.45-0.86) 
0.64 (0.47-0.88) 
White cell count 
(10
9
/L) 
78 0.35 0.95 (0.85-1.1)   
Platelets (10
9
/L)
†
 77 0.53 0.99 (0.95-1.0)   
Neutrophils(10
9
/L) 76 0.09 1.0 (1-1.0)   
Lymphocytes (10
9
/L) 76 0.67 1.01 (1.0-1.0)   
Serum creatinine 
(μmol/L)† 
80 0.09 1.01 (1.0-1.0)   
Serum albumin 
(g/dL)
†
 
64 0.11 0.62 (0.35-1.1)   
Serum protein (g/dL)
†
 60 0.01 1.1 (1.0-1.1) ----- 
----- 
----- 
----- 
Albumin creatinine 34 0.22 1.01 (0.99-1.03)   
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†
 Hazards ratio per 10 unit increase 
‡ Within the multivariate analysis two analysis were made (due to Pearson correlation coefficient of 
greater than 0.6, p<0.05). The first analysis included tubulointerstitial scarring however excluded 
eGFR, with the second analysis vice versa.  
 
  
ratio (mg/mmol)
†
 
Protein creatinine 
ratio (mg/mmol)
†
 
66 0.03 1.01 (1.0-1.0) ----- 
----- 
----- 
----- 
24hr urinary protein 
(mg/24hr)
†
 
66 0.03 1.0 (1-1.0) ----- 
----- 
----- 
----- 
eGFR (mL/min)
†
 79 <0.001
 0.73 (0.63-0.84) ----- 
----- 
----- 
----- 
Treatment      
Angiotensin-
converting-enzyme 
inhibitor 
73 0.68 0.85 (0.40-1.8)   
Angiotensin II 
receptor blocker 
71 0.63 1.3 (0.48-3.3)   
Angiotensin-
converting-enzyme 
inhibitor/ angiotensin 
II receptor blocker 
73 0.92 0.95 (0.39-2.3)   
Diuretics 71 0.45 1.3 (0.64-2.8)   
Immunosuppression 72 0.77 1.1 (0.50-2.6)   
 
Remission 
 
76 
 
0.01 
 
0.50 (0.30-0.84) 
 
----- 
----- 
 
----- 
----- 
Complete remission 76 0.02 0.24 (0.07-0.83) ----- 
----- 
----- 
----- 
Partial remission 75 0.93 0.96 (0.41-2.3)   
Relapse 43 0.07 0.40 (0.15-1.1)   
Steroid response 18 0.31 0.45 (0.10-2.1)   
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Table 5. Predictors towards the event of end stage renal disease 
 Unadjusted Cox regression 
 
Adjusted Cox regression‡  
Independent variable Numbers p-value Hazards ratio (95% CI) p-
value 
Hazards ratio 
(95% CI) 
Clinical factors      
Age in decades 92 0.01 1.4 (1.1-1.7) -----
 
-----
 
----- 
----- 
Male Gender 92 0.52 1.2 (0.64-2.4)   
Ethnicity 92 0.20 0.62 (0.29-1.3)   
Diabetes 90 0.049 2.0 (1.0-3.9) ----- 
----- 
----- 
----- 
Hypertension 88 0.26 1.8 (0.64-5.3)   
Hypercholesterolaemia 86 0.80 1.1 (0.51-2.4)   
Cardiovascular disease 85 0.35 1.4 (0.68-2.9)   
Ever smoked 84 0.75 1.1 (0.55-2.3)   
Infection 87 0.15 2.9 (0.67-12)   
Body Mass Index 82 0.38 0.84 (0.57-1.2)   
Haematuria 87 0.078 1.9 (0.93-3.7)   
Oedema 84 0.12 1.8 (0.86-3.8)   
Lesion factors      
Dual diagnosis  92 0.007 2.7 (1.3-5.5) 0.006 
0.027 
3.5 (1.4-8.4) 
2.8 (1.1-6.9) 
Diabetic nephropathy 92 0.002 4.3 (1.7-10.8) ----- 
----- 
----- 
----- 
IgA nephropathy 92 0.58 0.57 (0.077-4.2)   
Acute Tubular 
Necrosis 
92 0.034 3.7 (1.1-12) ----- 
----- 
----- 
----- 
NOS variant 92 0.201 2.5 (0.61-10)   
Tip variant 92 0.27 3.08 (0.42-22)   
Perihilar variant 92 0.78 0.049 (2.8x10
-11 – 
8.5x10
6
) 
  
Collapsing variant 92 0.54 0.048 (3.0x10
-6
- 8.9x10
2
)   
Cellular variant 92 0.83 1.2 (0.17-9.2)   
Tubulointerstitial 
Scarring  
92 <0.001
 3.04 (2.01-4.6) ----- 
----- 
----- 
----- 
Biochemical factors      
Haemoglobin (g/L)
†
 87 <0.001
 0.61 (0.51-0.74) ----- 
----- 
----- 
----- 
White cell count 
(10
9
/L) 
87 0.703 1.02 (0.92-1.1)   
Platelets (10
9
/L)
†
 86 0.47 0.99 (0.94-1.03)   
Neutrophils (10
9
/L) 85 0.16 1.002 (1.0-1.0)   
Lymphocytes (10
9
/L) 85 0.98 1.0 (0.98-1.02)   
Serum creatinine 
(μmol/L)† 
88 <0.001 1.03 (1.02-1.04) <0.001
 
----- 
1.04 (1.02-1.05) 
----- 
Serum albumin (g/dL)
†
 73 0.12 0.65 (0.38-1.1)   
Serum protein (g/dL)
†
 66 0.101 1.04 (0.99-1.08)   
Albumin creatinine 
ratio (mg/mmol)
†
 
38 0.39 1.009 (0.99-1.03)   
Protein creatinine ratio 
(mg/mmol)
†
 
76 0.033 1.009 (1.001-1.02)   
24hr urinary protein 76 0.053 1.001 (1.0-1.002)   
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†
 Hazards ratio per 10 unit increase 
‡ Within the multivariate analysis two analysis were made (due to Pearson correlation coefficient of 
greater than 0.6, p<0.05). The first analysis included tubulointerstitial scarring however excluded 
eGFR, with the second analysis vice versa.  
 
  
(mg/24hr)
†
 
eGFR (mL/min)
† 
87 <0.001 0.49 (0.38-0.63) ----- 
<0.001
 
----- 
0.57 (0.45-0.72) 
Treatment      
Angiotensin-
converting-enzyme 
inhibitor 
82 0.32 0.69 (0.34-1.4)   
Angiotensin II 
receptor blocker 
80 0.97 1.02 (0.39-2.7)   
Angiotensin-
converting-enzyme 
inhibitor/ angiotensin 
II receptor blocker 
82 0.26 0.64 (0.29-1.4)   
Diuretics 81 0.64 0.83 (0.38-1.8)   
Immunosuppression 81 0.33 1.5 (0.69-3.1)   
Remission 87 0.001 0.43 (0.25-0.72) 0.031 
0.005 
0.53 (0.301-
0.95) 
0.43 (0.45-0.72) 
Complete remission 87 0.006 0.13 (0.031-0.56) ----- 
----- 
----- 
----- 
Partial remission 86 0.92 1.04 (0.46-2.3)   
Relapse 48 0.087 0.42 (0.16-1.1)   
Steroid response 22 0.052 0.24 (0.056-1.01)   
Outcomes      
Doubled creatinine 91 <0.001 5.4 (2.4-11) <0.001
 
----- 
5.3 (2.09-13) 
----- 
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Table 6. Predictors towards the event of death 
 Unadjusted Cox regression Adjusted Cox regression‡ 
Independent variable Numbers p-value Hazards ratio (95% 
CI) 
p-
value 
Hazards ratio (95% 
CI) 
Clinical factors      
Age in decades 87 <0.001
 2.3 (1.6-3.4) 0.030
 
0.030
 
3.4 (1.1-10.5) 
3.4 (1.1-10.5) 
Gender 87 0.31 0.601 (0.22-1.6)   
Ethnicity 87 0.71 0.83 (0.31-2.2)   
Diabetes 80 0.15 2.07 (0.78-5.5)   
Hypertension 78 0.39 2.5 (0.32-18)   
Hypercholesterolaemia 79 0.52 0.72 (0.26-2.0)   
Cardiovascular disease 77 0.002 5.7 (1.9-17) ----- 
----- 
----- 
----- 
Ever smoked 76 0.82 1.1 (0.402-3.2)   
Infection 78 0.59 1.8 (0.23-14)   
Body mass index 74 0.029 0.53 (0.30-0.94) ----- 
----- 
----- 
----- 
Haematuria 82 0.14 2.06 (0.80-5.3)   
Oedema 78 0.74 1.2 (0.45-3.1)   
Lesion factors      
Dual diagnosis 87 0.30 1.8 (0.61-5.03)   
Diabetic nephropathy 87 0.089 3.0 (0.85-10.5)   
IgA nephropathy 87 0.99 0.99 (0.13-7.6)   
Acute tubular necrosis 87 0.25  3.4 (0.43-27)   
NOS variant 87 0.32 25 (0.047-13046)   
Tip variant 87 0.46 0.044 (1.3x10
5
 -158)   
Perihilar variant 87 0.88 0.049 (6.3 x 10
-19
 - 
3.8x10
15
) 
  
Collapsing variant 87 0.72 0.048 (3.6x10
-9
 – 
6.3x10
5
) 
  
Cellular variant 87 0.61 0.046 (3.7x10
-7
 – 
5.7x10
3
) 
  
Tubulointerstitial 
Scarring 
87 0.001 2.5 (1.4-4.3) ----- 
----- 
----- 
----- 
Biochemical factors      
Haemoglobin (g/L)
†
 82 0.001 0.69 (0.56-0.87) ----- 
----- 
----- 
----- 
White cell count 
(10
9
/L) 
82 0.051 1.1 (1.0-1.3)   
Platelets (10
9
/L)
† 
81 0.04 0.92 (0.85-1.0) ----- 
----- 
----- 
----- 
Neutrophils (10
9
/L) 80 0.56 1.0 (0.98-1.009)   
Lymphocytes (10
9
/L) 80 0.001  0.21 (0.09-0.51) ----- 
----- 
----- 
----- 
Serum creatinine 
(μmol/L)† 
84 0.002 1.02 (1.0-1.03) ----- 
----- 
----- 
----- 
Serum albumin (g/dL)
† 
70 0.43 0.73 (0.33-1.6)   
Serum protein (g/dL)
† 
64 0.02  1.1 (1.0-1.1) ----- 
----- 
----- 
----- 
Albumin creatinine 
ratio (mg/mmol)
† 
58 0.04 1.0 (1.0-1.1) ----- 
----- 
----- 
----- 
Protein creatinine ratio 67 0.97 1.0 (0.99-1.0)   
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†
 Hazards ratio per 10 unit increase 
‡ Within the multivariate analysis two analysis were made (due to Pearson correlation coefficient of 
greater than 0.6, p<0.05). The first analysis included tubulointerstitial scarring however excluded 
eGFR, with the second analysis vice versa.  
 
(mg/mmol)
† 
24hr urinary protein 
(mg/24hr)
† 
67 0.66 1.0 (1.0-1.0)   
eGFR (mL/min)
† 
83 <0.001
 0.62 (0.48 – 0.80) ----- 
----- 
----- 
----- 
Treatment      
Angiotensin-
converting-enzyme 
inhibitor 
73 0.039 0.33 (0.11-0.94)   
Angiotensin II 
receptor blocker 
70 0.85 0.86 (0.19-3.9)   
Angiotensin-
converting-enzyme 
inhibitor/ angiotensin 
II receptor blocker 
72 0.02 0.26 (0.089-0.78) ----- 
----- 
----- 
----- 
Diuretics 70 0.77 1.2 (0.39-3.5)   
Immunosuppression 72 0.35 1.8 (0.54-5.7)   
Remission 81 0.094 0.56 (0.28-1.1)   
Complete remission 81 0.21 0.38 (0.09-1.7)   
Partial remission 81 0.55 0.68 (0.19-2.4)   
Relapse 48 0.64 0.74 (0.21-2.6)   
Steroid response 15 0.19 0.20 (0.02-2.2)   
Outcomes      
ESKD 78 0.09 2.7 (0.87-8.6)   
Doubled creatinine 84 0.50 1.4 (0.53-3.7)   
